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Abstract
Pediatric sarcomas, including rhabdomyosarcomas, Ewing’s sarcoma, and osteosarcoma, are aggressive tumors with poor
survival rates. To overcome problems associated with nonselectivity of the current therapeutic approaches, targeted
therapeutics have been developed. Currently, an increasing number of such drugs are used for treating malignancies of
adult patients but little is known about their effects in pediatric patients. We analyzed expression of 24 clinically approved
target genes in a wide variety of pediatric normal and malignant tissues using a novel high-throughput systems biology
approach. Analysis of the Genesapiens database of human transcriptomes demonstrated statistically significant up-
regulation of VEGFC and EPHA2 in Ewing’s sarcoma, and ERBB3 in alveolar rhabdomyosarcomas. In silico data for ERBB3 was
validated by demonstrating ErbB3 protein expression in pediatric rhabdomyosarcoma in vitro and in vivo. ERBB3
overexpression promoted whereas ERBB3-targeted siRNA suppressed rhabdomyosarcoma cell gowth, indicating a functional
role for ErbB3 signaling in rhabdomyosarcoma. These data suggest that drugs targeting ErbB3, EphA2 or VEGF-C could be
further tested as therapeutic targets for pediatric sarcomas.
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Introduction
According to the European Medicines Agency (EMEA) 50–90%
of drugs have never been tested for use in children [1,2]. Still drugs
are frequently used for pediatric patients off-label, risking activity
and raising concerns about adverse effects [3]. Several new cancer
drugs targeting specific signaling molecules have recently been
approved for clinical use [4,5]. Little is known about their activities
in pediatric patients, or about the presence of their target proteins
in pediatric cancer tissues.
Pediatric sarcomas, including rhabdomyosarcomas, Ewing’s
sarcoma, and osteosarcomas, are highly malignant tumors in
children, adolescents and young adults, and account for approx-
imately 6% of all childhood malignancies [6]. Sarcomas have a low
survival rate despite multimodal treatment, including surgery and/
or radiotherapy in combination with multidrug adjuvant chemo-
therapy. For localized disease, the overall 5-year survival rates
approach 60–70% [7], but metastatic sarcomas have a significantly
less favorable prognosis with 5-year overall survival ranging
between 10% and 30% [8,9]. The quality of life of long-term
survivors may also be compromised [10]. Thus, innovative new
therapies are needed.
Systems biological and computational approaches can benefit
cancer research and drug development. Systems level high-
throughput analyses of cancer samples generate an extremely
wide range of data about somatic and germ-line mutations, as well
as about cancer-specific transcript and protein expression profiles.
Electronic databases can be used to explore gigabytes of data from
cancer genomes, transcriptomes and proteomes (genes, messenger
RNAs, proteins, and their modifications) that are generated in
independent projects worldwide. Converting the knowledge
obtained using these omics techniques into clinical applications
may provide novel and more specific options for cancer therapy
[11].
In this study, the Genesapiens in silico transcriptomics database
(www.genesapiens.com) [12] including calibrated data from 9783
publicly available Affymetrix analyses was used to identify
transcripts overrepresented in human pediatric sarcomas. Differ-
ential expression analysis of 24 target genes for clinically available
therapeutic antibodies, tyrosine kinase inhibitors, and proteasomal
inhibitors demonstrated specific up-regulation of transcripts
encoding ErbB3 in pediatric rhabdomyosarcomas, and transcripts
encoding VEGF-C and EphA2 in Ewing’s sarcoma. The data
were validated by demonstrating ErbB3 protein expression in
clinical rhabdomyosarcoma and suppression of rhabdomyosarco-
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ma cell growth by RNA interference-mediated down-regulation of
ErbB3. Thus, currently available targeted cancer drugs, such as
inhibitors of the ErbB or VEGF receptors, or dasatanib with
affinity for EphA2 [13], could be further evaluated as novel
therapeutics for pediatric bone tumors. These data provide both
candidates for novel drug targets as well as suggest novel
indications for existing cancer drugs for the therapy of pediatric
sarcomas.
Methods
Affymetrics Data Collection
The Genesapiens in silico database of human transcriptomes was
constructed by collecting data from 9783 publicly available
Affymetrics microarray experiments in the form of CEL files as
the source material (www.genesapiens.com). The data including
arrays of normal and pathological human in vivo tissue samples
were preprocessed and normalized, as previously described [12].
Altogether, the samples covered 15 pediatric cancer tissues
(n = 1015) and 11 different pediatric normal tissues (n = 154).
The normal samples represented hematological (n = 80), connec-
tive (n = 59), urogenital (n = 9), nervous (n = 4), and endocrine
(n = 2) tissues. Samples from patients of 16 years or younger were
defined as pediatric samples.
Gene Expression Heatmaps for Clinically Relevant 24
Human Cancer Genes
Body-wide expression maps of 24 known cancer gene targets
were generated with hierarchical clustering (Euclidean distance) of
mean expression profile for genes across 4 human pediatric tumor
subtypes (n = 40) of muscle or mesenchyme origin and 4 pediatric
normal tissues (n = 73). The 4 control tissues were selected from
the available pediatric data as they represented available primary
tissues from which Ewing’s- or rhabdomyosarcomas have been
clinically diagnosed or speculated to origin from [9,14,15]. Values
for each gene across tumor and normal samples were mean
centred at 0 with a standard deviation of 1. Tumor and tissue
specific genes acquire a high score in the overall heatmap and can
be identified in spots with a strong red color. Red color indicates
increased level of expression. Blue color indicates decreased level
of expression.
Body-wide Expression Profiles
The expression profile of a single gene across all pediatric tissues
was visualized with custom designed body-wide expression plots.
Body-wide expression profiles show the expression of a single gene
at the level of individual pediatric samples, while its layout allows
easy analysis of the biological or medical significance of the profile.
The y-axis defines the expression level of the gene and the x-axis
Figure 1. Hierarchial clustering of validated therapeutic target genes in rhabdomyosarcomas and Ewing’s sarcomas. The red boxes
illustrate mRNA expression levels exceeding the mean expression per gene in the analyzed tissues, whereas the blue boxes illustrate mRNA
expression levels lower than the mean expression per gene. The number of samples analyzed per tissue type is given in parentheses.
doi:10.1371/journal.pone.0050819.g001
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defines all samples arranged into fixed order by the type of sample
(healthy, cancer) and subsequently by different tissue types
(hematological, connective and muscular, nervous, urogenital
and endocrine). Thus, each dot describes the expression levels of
a particular gene in one sample. The anatomical origin of each
sample is shown in the color bar at the bottom of the image.
Tissues expressing the gene at more than one standard deviation
higher than the baseline level for that gene across all samples are
colored and displayed at the top.
Boxplots
In the boxplots, the expression profiles of a single gene were
displayed grouped into pediatric malignant samples (red boxes).
All tumor samples for one tumor type were compared to all other
pediatric samples (normal and cancer samples). The boxplots show
the dispersion and skewness in the data. The data were split into
five parts [lower quartile (Q1), median (Q2), upper quartile (Q3),
and largest observation that is considered a non-outlier in
a statistical sense] represented by the horizontal bars. The samples
displayed above the last bar are considered outliers, representing
Figure 2. Expression profile of EPHA2 in pediatric healthy and cancer tissues. A) Body-wide expression profile of the EPHA2 gene across the
database. Each dot represents the expression of EPHA2 in one sample. Anatomical origins of each sample are marked in color bars below the gene
plot. The EPHA2 gene is highly expressed in malignant connective and muscular tissue samples (green dots). B) Box plot analysis of the EPHA2 gene
expression levels across a variety of pediatric cancer samples. EPHA2 is particularly highly expressed in osteosarcoma and Ewing’s sarcoma. NOS, not
otherwise specified.
doi:10.1371/journal.pone.0050819.g002
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data observations which lie more than 1.5*inter-quartile range
higher than the third quartile.
Plasmids, siRNAs, and Transfection
RD rhabdomyosarcoma cells (ATCC CLL-136) were trans-
fected with pcDNA3.1ErbB3 (insert includes nucleotides 277–4305
from GenBank accession NM_001982) or an empty pcDNA3.1-
neo(–) vector (Invitrogen) using FuGENE 6 (Roche). To down-
regulate endogenous ErbB3 expression, RD cells were transfected
with siRNA targeting ERBB3 (E3 Sitha Custom Select siRNA;
Ambion) or AllStars negative control siRNA (Qiagen) using
Lipofectamine 2000 (Invitrogen) following manufacturers’ instruc-
tions.
Western Blotting
For ErbB3 protein expression analysis, RD transfectants were
lysed 24 hours after transfections and analyzed by Western
blotting with anti-ErbB3 (sc-285; Santa Cruz Biotechnology, Inc.),
as previously described [16]. Loading was controlled by reblotting
with anti-actin (sc-1616; Santa Cruz Biotechnology, Inc.).
Figure 3. Expression profile of VEGFC in pediatric healthy and cancer tissues. A) Body-wide expression profile of the VEGFC gene across the
database. Each dot represents the expression of VEGFC in one sample. Anatomical origins of each sample are marked in color bars below the gene
plot. The VEGFC gene is highly expressed in samples originating from malignant connective or muscular tissue (green dots). The ten green dots
forming a separate group with high VEGFC expression all represent samples from Ewing’s sarcoma. B) Box plot analysis of the VEGFC gene expression
levels across a variety of pediatric cancer samples. VEGFC is particularly highly expressed in Ewing’s sarcoma. NOS, not otherwise specified.
doi:10.1371/journal.pone.0050819.g003
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Immunohistochemistry
Four-micrometer thin paraffin sections representing pediatric
alveolar rhabdomyosarcoma, pediatric Ewing’s sarcoma, or
normal adult stomach were analyzed for ErbB3 or EphA2
expression using sc-285 (1:100 dilution) or sc-924 (1:250 dilution)
(Santa Cruz Biotechnology, Inc.) primary antibodies, respectively.
After treatment with ChemMate (DakoCytomation Denmark A/
S) antigen retrieval solution at pH 9.0, the staining was carried out
using automated immunostainer (Lab Vision Autostainer), and
Brigth Vision Poly-HRP-anti Ms/Rb/Rt IgG kit (Immuno Logic).
MTT Proliferation Assay
To address the effect of ERBB3 on cell growth, RD cells were
plated onto 96-well plates (Nunc) at a density of 5000–6000 cells/
well in DMEM (Gibco) containing 10% FCS (Biochrom) 24 hours
after transfections with plasmid or siRNA constructs, respectively.
The number of viable cells was estimated at indicated time points
after plating using CellTiter 96 nonradioactive cell proliferation
assay (MTT; Promega).
Figure 4. Expression profile of ERBB3 in pediatric healthy and cancer tissues. A) Body-wide expression profile of the ERBB3 gene across the
database. Each dot represents the expression of ERBB3 in one sample. Anatomical origins of each sample are marked in color bars below the gene
plot. The ERBB3 gene is highly expressed in malignant connective and muscular tissue samples (green dots). B) Box plot analysis of the ERBB3 gene
expression levels across a variety of pediatric cancer samples. ERBB3 is particularly highly expressed in alveolar rhabdomyosarcomas. NOS, not
otherwise specified.
doi:10.1371/journal.pone.0050819.g004
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Statistical Analyses
Gene expression differences associated with a particular pedi-
atric cancer were measured and ranked using gene tissue index
(GTI) outlier statistic, as previously described [17]. Expression
values of each gene in a single pediatric tumor (test group) were
compared with the expression levels in other pediatric normal and
cancer samples combined (reference group). This is a common
approach used to find cancer biomarkers based on gene
expression. For example, gastrointestinal stromal tumor (GIST)
patients with high amplification of KIT benefit from c-KIT
inhibitors like imatinib [18]. Similarly we wanted to identify drug
targets showing specific expression in one pediatric tumor.
The Fisher’s exact test (Cox, 1970) was used to test for the fold-
change difference of each gene between the test group and the
reference group. To correct for multiple testing, we applied
Bonferroni and Benjamin Hochberg multiple testing correction
methods for assessing the significance of the outlier differences
(corrected P,0.05).
Statistical analysis of the MTT proliferation assay was carried
out with Student’s independent samples t-test. Six to eight parallel
samples were analyzed for each time point, and each experiment
was repeated at least twice.
Results
Targets of Approved Cancer Drugs in Pediatric Sarcomas
Publicly available Affymetrix microarray data from Genesa-
piens (www.genesapiens.com) database were analyzed to profile
Figure 5. Expression and function of ErbB3 in rhabdomyosarcoma. (A) Western analysis of ErbB3 expression in RD cells transfected or not
with a plasmid encoding ErbB3 or an empty vector control (lanes 1–3), or with ERBB3-targeting or control siRNA (lanes 4–5). Membranes were
reblotted with anti-actin to control loading. (B–D) Immunohistochemical analysis of ErbB3 expression in normal adult human stomach (B) and in two
samples representing pediatric alveolar rhabdomyosarcoma (C,D). (E,F) MTT proliferation analysis of the effect of ERBB3 overexpression (E) or siRNA-
mediated ERBB3 down-regulation on the growth of RD cell transfectants. Expression of ErbB3 in the transfectants is shown in (A). *, P,0.001 when
compared to control. Scale bar in (B–D), 100 mm.
doi:10.1371/journal.pone.0050819.g005
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the expression of 24 genes in various malignant (n = 1015) and
non-neoplastic (n = 154) pediatric tissue samples. Data from
Genesapiens were normalized using the array-generation-based
gene centering (AGC normalization algorithm). The AGC
normalization method effectively removes platform and batch
effects that may result from integrating data from multiple sources,
as described in detail by Kilpinen et al. [12].
The 24 genes were selected for the analysis as they are known
targets for molecularly targeted drugs currently in use for adult
malignancies. A focused heatmap analysis of the 24 selected cancer
drug targets in pediatric sarcomas and selected control tissues
indicated that a few of the targets were indeed selectively
overexpressed in pediatric Ewing’s sarcoma and in embryonal
and alveolar rhabdomyosarcoma when compared to normal
muscle tissue and hematopoietic cells (Fig. 1). EPHA2 (encoding
EphA2, ephrin type A receptor 2), VEGFC (vascular endothelial
growth factor-C), and FKBP1A (FK506 binding protein 1A) were
overexpressed in Ewing’s sarcomas. In contrast, EGFR (epidermal
growth factor receptor), VEGFR2 (VEGF receptor 2=KDR), and
PDGFRA (platelet-derived growth factor receptor a) were over-
expressed in embryonal, and ERBB3 (ErbB3) in alveolar and
unclassified rhabdomyosarcomas (Fig. 1). Overexpression of these
genes in the specific sarcoma subtypes was also statistically
significant when the whole pediatric Genesapiens database was
explored for differential expression using Fisher’s exact test (File
S1). Moreover, EPHA2 and VEGFC ranked high in Ewing’s
sarcoma, PDGFRA in embryonal rhabdomyosarcoma, and ERBB3
in alveolar and unclassified rhabdomyosarcoma, when an outlier
expression analysis of the 24 selected cancer drug targets in
pediatric sarcomas across the Genesapiens database was carried
out using a non-parametric algorithm GTI, a method designed to
detect outlier overexpression levels in subsets of samples [17] (File
S1).
Body-wide Expression and Boxplot Analyses EPHA2,
VEGFC, and ERBB3
To further address the relative expression of the candidate
target genes in the context of all pediatric tissues, body-wide
expression analyses were carried out with all 1169 samples
representing various malignant and non-neoplastic pediatric
tissues. Body-wide expression profiles for EPHA2 (Fig. 2A), VEGFC
(Fig. 3A), and ERBB3 (Fig. 4A) indicated the most selective
overexpression in malignant connective tissues, when compared to
all other pediatric cancer and healthy normal tissues. Boxplot
analyses providing comparisons within the different pediatric
cancer samples indicated selective up-regulation of the mean
expression of EPHA2 and VEGFC in Ewing’s sarcoma (Fig. 2B and
3B). High EPHA2 expression levels were also observed in pediatric
osteosarcomas (Fig. 2B) in a small number of samples (n = 3). The
overexpression of ERBB3 seemed to be relatively specific for the
alveolar subtype of pediatric rhabdomyosarcoma (Fig. 4B). Fisher’s
exact test demonstrated that the relative overexpression EPHA2
and VEGFC in Ewing’s sarcoma was 15- and 17-fold, respectively,
when compared to all pediatric cancer and normal samples
(P,0.001 for both comparisons) (File S1). The relative over-
expression of ERBB3 in alveolar and in unclassified (not otherwise
specified) rhabdomyosarcoma samples was 5-fold (P=0.04) and 8-
fold (P,0.001), respectively (File S1).
Validation of Expression and Activity of ErbB3 in
Rhabdomyosarcoma
While tyrosine kinase inhibitors blocking EphA2 or VEGF-C
signaling are already being tested as potential targets for sarcomas
[19,20], no information about the biological role of ErbB3 in
pediatric rhabdomyosarcoma is currently available. To determine
the expression of ErbB3 protein in a rhabdomyosarcoma cell line
RD, and to characterize the specificity of the ErbB3 antibody sc-
285 used, Western analyses were carried out. The anti-ErbB3
detected a single major band of approximately 180 kD in parental
RD cells (Fig. 5A, lane 1). The intensity of the band was
significantly increased by plasmid-mediated ERBB3 overexpres-
sion (Fig. 5A, lane 3 vs. 2), and suppressed by RNA interference-
mediated ERBB3 down-regulation (Fig. 5A, lane 5 vs. 4).
Immunohistochemical analysis with the same anti-ErbB3 demon-
strated strong staining in the gland epithelium of normal gastric
corpus (Fig. 5B), consistent with the previously described ErbB3-
specific staining pattern [21] (www.proteinatlas.org). When ten
clinical samples representing pediatric alveolar rhabdomyosarco-
ma were analyzed for ErbB3 expression, strong cytoplasmic
expression was detected in one (Fig. 5C), and weak to moderate
expression in two (Fig. S1D), whereas seven samples demonstrated
no expression (Fig. 5D; data not shown). Six out of six analyzed
Ewing’s sarcoma samples were totally negative for ErbB3
immunoreactivity (Fig. S1C), indicating specificity of ErbB3
overexpression in pediatric rhabdomyosarcoma, and consistent
with the in silico findings (Fig. 4B). As a positive control for the
Ewing’s samples, and again consistent with the in silico findings
(Fig. 2B), all ten analyzed Ewing’s sarcoma samples demonstrated
variable degrees of immunohistochemical EphA2 expression (Fig.
S1A).
Finally, to address the effects of both gain-of-function and loss-
of-function of ERBB3 for the growth of rhabdomyosarcoma cells,
RD cell transfectants overexpressing ERBB3 or with siRNA-
targeted ERBB3 (Fig. 5A) were analyzed using MTT assays
measuring the amount of viable cells. Overexpression of ErbB3
significantly promoted the growth of RD cells (Fig. 5E), whereas
ErbB3 down-regulation resulted in significantly reduced RD cell
growth (Fig. 5F). Taken together, these findings indicated that,
consistent with the data from the in silico approach, ErbB3 protein
was expressed in a subpopulation of pediatric alveolar rhabdo-
myosarcoma patients, and that ErbB3 expressed in RD cells was
biologically significant in promoting growth.
Discussion
The survival rates for many pediatric sarcomas have remained
poor for the past decades and novel therapeutics have been slow to
enter into pediatric practice.
We found that the gene encoding receptor tyrosine kinase
EphA2, the ephrin type A receptor 2, is highly expressed in
pediatric Ewing’s- and osteosarcomas. The EphA2 receptor and
the ephrinA1 ligand have previously been found to be over-
expressed in the majority of human osteosarcomas [22]. Our
immunohistochemical analysis demonstrated that EphA2 was also
expressed at the protein level in ten out of ten samples representing
clinical pediatric Ewing’s sarcoma. Recent studies have indicated
Eph receptors and their ephrin ligands roles in promoting tumor
formation and progression, as well as in stimulating tumor
angiogenesis and metastasis [23–25]. Thus, the ephrin/Eph
receptor system has emerged as an attractive therapeutic target
in a number of aggressive adult tumors including breast, lung,
colon, kidney, ovarian, and prostate cancer, as well as melanoma
and neuroblastoma [26,27].
Dasatinib is a tyrosine kinase inhibitor that targets several
tyrosine kinases, including the Eph receptors (EphA and EphB),
PDGFRb, c-Kit, Src family kinases, and the Bcr-Abl fusion
protein [28]. It has been approved for use in Philadelphia
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chromosome-positive chronic myelogenous leukemia. Consistent
with our finding, dasatinib has also been shown to inhibit
migration of Ewing’s sarcoma, osteosarcoma and rhabdomyosar-
coma cell lines, and selectively block the survival of Ewing’s- and
osteosarcoma cells [19]. Moreover, dasatinib has been shown to
suppress growth of three out of five osteosarcoma tumor
xenografts [29]. Thus, dasatinib could be tested as novel
therapeutics for pediatric Ewing’s- and osteosarcomas.
In addition to EPHA2, we found that VEGFC expression was
exceptionally high in pediatric Ewing’s sarcomas. Possibly due to
the low local concentrations of the soluble VEGF-C protein in vivo,
or to the characteristics of the antibodies tested, we were however
not able to immunohistochemially address the expression of
VEGF-C protein in paraffin-embedded tissue sections (data not
shown). VEGF-C is a member of the VEGF family of ligands, that
regulates both angiogenesis and lymphangiogenesis by interacting
with the VEGF receptors VEGFR-2 and VEGFR-3 [30]. The
growth, migration and dissemination of sarcoma cells may also be
dependent on angio- and lymphangiogenesis [31–33].
Broad-spectrum kinase inhibitors targeting VEGFRs, such as
sunitinib, semaxanib (SU5416) and SU6668 and the VEGF-A
antibody bevacizumab, have been shown to inhibit growth of
Ewing’s sarcoma in mouse xenograft models [34,35]. Cediranib
(AZD2171), a VEGFR family inhibitor that also blocks VEGF-C-
induced VEGFR-3 activity [36], inhibits growth of pediatric
sarcoma xenografts (Ewing’s-, rhabdoid- and osteosarcomas) in
mice [37]. A recent phase I trial of cediranib in children and
adolescents also demonstrated responses in patients with Ewing’s-
or synovial sarcoma [20]. In addition, clinical trials with broad
spectrum inhibitors sorafenib and pazopanib, that both also target
VEGFR-3, have shown improved progression-free survival rates in
adult angio-, leimomyo- and synovial sarcomas [38,39]. Of these
drugs, sunitinib has been approved for renal cell carcinoma and
gastrointestinal stromal tumors, bevacizumab for colorectal
cancer, non-small cell lung cancer, glioblastoma, renal cell
carcinoma and breast cancer, and pazopanib for renal cell
carcinoma. Semaxanib and cediranib are presently in phase I
clinical trials. Taken together, broad spectrum VEGFR inhibitors,
currently in use or tested for adult cancer patients, may slow
progression of pediatric sarcomas.
Finally, we found that ERBB3 (HER3) transcript is highly
expressed in pediatric alveolar rhabdomyosarcomas. Down-
regulation of ErbB3 levels also led to suppression of rhabdomyo-
sarcoma cell growth in vitro. Moreover, ErbB3 protein was present
in three out of ten immunohistochemically analyzed clinical
samples. It is of note, that both the in silico as well as the in vivo
approaches indicated significant quantitative variation in ErbB3
expression between individual samples. While the percentage of
ErbB3-positive alveolar rhabdomyosarcomas needs to be verified
in larger clinical series, our findings suggest that ErbB3 targeting
could be effective only for a subpopulation of patients, and ErbB3
immunohistochemistry considered as a predictive test. ErbB3
belongs to the human epidermal growth factor receptor family of
receptor tyrosine kinases together with EGFR (ErbB1, HER1),
ErbB2 (HER2), and ErbB4 (HER4) [5,40]. Both EGFR and
ErbB2 have been established as clinically relevant drug targets,
and the therapeutic antibodies trastuzumab, cetuximab and
panitumumab, as well as the tyrosine kinase inhibitor erlotinib,
gefitinib and lapatinib, are currently used in the therapy of adult
patients with breast, gastric, colorectal, head and neck, lung, or
pancreatic cancer [5,41]. As ErbB receptors have a tendency to
form heterodimers some of these drugs indirectly also affect ErbB3
signaling [42]. In addition, pharmaceutical companies are
currently in the process of developing therapeutic antibodies that
would directly block the function of ErbB3.
Two phase I studies with gefitinib, an EGFR inhibitor,
suggested that gefitinib is safe and well tolerated in children with
solid tumors, but had limited clinical activity. However, in the two
studies one out of three patients with Ewing’s sarcoma had a partial
response [43,44]. Erlotinib, another EGFR inhibitor, has also
been reported to be well tolerated in children with solid tumors,
but to lack significant antitumor activity against rhabdomyo- or
osteosarcomas [44,45]. Currently, no data are available about the
activity of ErbB2- or directly ErbB3-targeted therapy in pediatric
sarcoma.
In summary, we found that EPHA2 and VEGFC are highly
expressed in pediatric Ewing’s sarcomas and ERBB3 in pediatric
rhabdomyosarcomas. Thus, currently available targeted cancer
drugs such as inhibitors of the EphA2, VEGF or ErbB receptors
could be tested as novel therapeutics for pediatric bone tumors.
These cancer types are currently treated with cytotoxic chemo-
therapy with limited clinical effect and a wide range of adverse
effects. In the future, identification of druggable targets in pediatric
tumors may enable customizing the most effective treatment for
individual patients while minimizing unnecessary side effects.
However, characterization of the optimal drug targets and the
design of future clinical investigations remain a great challenge.
Supporting Information
Figure S1 EphA2 but not ErbB3 is expressed in
pediatric Ewing’s sarcoma. Immunohistochemical analysis
demonstrates that EphA2 is expressed in pediatric Ewing’s
sarcoma (A), as well as in the positive control tissue, adult human
stomach (B). In contrast, Ewing’s sarcoma is negative for ErbB3
(C), while a sample of pediatric alveolar rhabdomyosarcoma
demonstrates ErbB3-positivity (an example of weak staining) (D).
(PDF)
File S1 Statistical analysis of drug target expression in
pediatric sarcomas.
(XLS)
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